PATENT CLAIM ANALYSIS

Application Number: 15860849
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["514", "253040"]

Abstract:
Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3  and X 4  have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Claim (Index 20):
The method of  claim 1 , wherein the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), breast cancer, cervical cancer, colorectal cancer, ganglioneuromatosis of the gastroenteric mucosa, gastric cancer, gastrointestinal stromal tumors, glioma, leukemia, lung cancer, lymphoma, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), multiple myeloma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, papillary renal cell carcinoma, paraganglioma, parathyroid hyperplasia, pheochromocytoma, and thyroid cancer.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 1.63462
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15860781', '15858658', '15860852', '15860808', '15860894']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8720739111681381
- 35 USC 102 Novelty (BERT): 0.6086804822261512
- Combined Prediction Score: 0.8457345682739396
- Mean Citation Score: 555.59615
- Max Citation Score: 589.4416
- Similarity Product: 499.8820610897063

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test